Skip to main content

Caprylate-Conjugated Cisplatin for the Development of Novel Liposomal Formulation

AAPS PharmSciTech volume 15, pages 845–857 (2014)Cite this article

Abstract

Cisplatin, first (platinum) compound to be evolved as an anticancer agent, has found its important place in cancer chemotherapy. However, the dose-dependent toxicities of cisplatin, namely nephrotoxicity, ototoxicity, peripheral neuropathy, and gastrointestinal toxicity hinder its widespread use. Liposomes can reduce the toxicity of cisplatin and provide a better therapeutic action, but the low lipid solubility of cisplatin hinders its high entrapment in such lipid carrier. In the present investigation, positively charged reactive aquated species of cisplatin were complexed with negatively charged caprylate ligands, resulting in enhanced interaction of cisplatin with lipid bilayer of liposomes and increase in its encapsulation in liposomal carrier. Prepared cisplatin liposomes were found to have a vesicular size of 107.9 ± 6.2 nm and zeta potential of −3.99 ± 3.45 mV. The optimized liposomal formulation had an encapsulation efficiency of 96.03 ± 1.24% with unprecedented drug loading (0.21 mg cisplatin / mg of lipids). The in vitro release studies exhibited a pH-dependent release of cisplatin from liposomes with highest release (67.55 ± 3.65%) at pH 5.5 indicating that a maximum release would occur inside cancer cells at endolysosomal pH. The prepared liposomes were found to be stable in the serum and showed a low hemolytic potential. In vitro cytotoxicity of cisplatin liposomes on A549 lung cancer cell line was comparable to that of cisplatin solution. The developed formulation also had a significantly higher median lethal dose (LD50) of 23.79 mg/kg than that of the cisplatin solution (12 mg/kg). A promising liposomal formulation of cisplatin has been proposed that can overcome the disadvantages associated with conventional cisplatin therapy and provide a higher safety profile.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

References

  1. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep. 2003;10(6):1663–82.

    CAS  PubMed  Google Scholar 

  2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84. doi:10.1038/nrc2167.

    CAS  PubMed  Article  Google Scholar 

  3. Kelland LR, Farrell NP. Platinum-based drugs in cancer therapy. Totowa: Humana Press; 2000.

    Book  Google Scholar 

  4. Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther. 2007;5:537–83.

    Google Scholar 

  5. Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs. 2007;16(7):1009–21. doi:10.1517/13543784.16.7.1009.

    CAS  PubMed  Article  Google Scholar 

  6. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Futur Oncol (Lond Engl). 2009;5(1):33–42. doi:10.2217/14796694.5.1.33.

    CAS  Article  Google Scholar 

  7. Berners-Price SJ, Frenkiel TA, Frey U, Ranford JD, Sadler PJ. Hydrolysis products of cisplatin: pKa determinations via [1H, 15N] NMR spectroscopy. J Chem Soc Chem Commun. 1992;10:789–91.

    Article  Google Scholar 

  8. Orton DM, Gretton VA, Green M. Acidity constants for cis-diaquadiammineplatinum (II), the aquated form of cisplatin. Inorg Chim Acta. 1993;204(2):265–6.

    CAS  Article  Google Scholar 

  9. Speelmans G, Sips WHHM, Grisel RJH, Staffhorst RWHM, Fichtinger-Schepman AMJ, Reedijk J, et al. The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim Biophys Acta (BBA) Biomembr. 1996;1283(1):60–6.

    Article  Google Scholar 

  10. Johnson NP, Butour J-L, Villani G, Wimmer FL, Defais M, Pierson V, et al. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog Clin Biochem Med. 1989;10:1–24.

    CAS  Article  Google Scholar 

  11. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 2002;79(1–3):123–35.

    CAS  PubMed  Article  Google Scholar 

  12. Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. Pharm Dev Technol. 2005;9(3):277–89. doi:10.1081/PDT-200031432.

    Article  Google Scholar 

  13. Hwang TL, Lee WR, Hua SC, Fang JY. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. J Dermatol Sci. 2007;46(1):11–20. doi:10.1016/j.jdermsci.2006.12.011.

    CAS  PubMed  Article  Google Scholar 

  14. Molina EF, Pulcinelli SH, Santilli CV, Blanchandin S, Briois V. Controlled cisplatin delivery from Ureasil-PEO1900 hybrid matrix. J Phys Chem B. 2010;114(10):3461–6. doi:10.1021/jp9097638.

    CAS  PubMed  Article  Google Scholar 

  15. de Kroon AI, Staffhorst RW, Kruijff B, Burger KN. Cisplatin nanocapsules. Methods Enzymol. 2005;391:118–25. doi:10.1016/S0076-6879(05)91006-9.

    PubMed  Article  Google Scholar 

  16. Akimaru K, Auzenne E, Akimaru Y, Leroux ME, Hayman AC, Utsumi T, et al. Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2. Cytokines Mol Ther. 1995;1(3):197–210.

    CAS  PubMed  Google Scholar 

  17. Utsumi T, Hung MC, Klostergaard J. Preparation and characterization of liposomal-lipophilic tumor necrosis factor. Cancer Res. 1991;51(13):3362–6.

    CAS  PubMed  Google Scholar 

  18. Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, et al. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex. J Control Release Off J Control Release Soc. 2007;121(1–2):110–23. doi:10.1016/j.jconrel.2007.05.037.

    CAS  Article  Google Scholar 

  19. Yan X, Gemeinhart RA. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J Control Release. 2005;106(1–2):198–208. doi:10.1016/j.jconrel.2005.05.005.

    CAS  PubMed  Article  Google Scholar 

  20. Abra RM, Reis K. Liposomes containing a cisplatin compound. United States 2000.

  21. Anilanmert B, Yalçin G, Ariöz F, Dölen E. The spectrophotometric determination of cisplatin in urine, using o-phenylenediamine as derivatizing agent. Anal Lett. 2001;34(1):113–23. doi:10.1081/AL-100002709.

    CAS  Article  Google Scholar 

  22. Oku N, Namba Y. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol. 2005;391:145–62. doi:10.1016/s0076-6879(05)91008-2.

    CAS  PubMed  Article  Google Scholar 

  23. Freshney RI. Cytotoxicity. Culture of animal cells: a manual of basic technique. 5th ed. Hoboken: John Wiley & Sons, Inc; 2005. p. 365–81.

    Book  Google Scholar 

  24. OECD Guideline for Testing of Chemicals. OECD Test Guideline 425: up-and-down procedure. OECD Publishing, Organization for Economic Co-operation and Development 2001.

  25. Heurtault B, Saulnier P, Pech B, Proust J-E, Benoit J-P. Physico-chemical stability of colloidal lipid particles. Biomaterials. 2003;24(23):4283–300. doi:10.1016/S0142-9612(03)00331-4.

    CAS  PubMed  Article  Google Scholar 

  26. Cacela C, Hincha DK. Low amounts of sucrose are sufficient to depress the phase transition temperature of dry phosphatidylcholine, but not for lyoprotection of liposomes. Biophys J. 2006;90(8):2831–42. doi:10.1529/biophysj.105.074427.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  27. FDA Draft Guidance for Industry on Liposome Drug Products, United States Food and Drug Administration 2002.

  28. Fakes MG, Dali MV, Haby TA, Morris KR, Varia SA, Serajuddin AT. Moisture sorption behavior of selected bulking agents used in lyophilized products. PDA J Pharm Sci Technol. 2000;54(2):144–9.

    CAS  PubMed  Google Scholar 

  29. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–84.

    CAS  PubMed  Article  Google Scholar 

  30. Moreira JN, Gaspar R, Allen TM. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta. 2001;1515(2):167–76.

    CAS  PubMed  Article  Google Scholar 

  31. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta. 1989;981(1):27–35.

    CAS  PubMed  Article  Google Scholar 

  32. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992;1103(1):94–100.

    CAS  PubMed  Article  Google Scholar 

  33. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol Off J Eur Soc Med Oncol. 2001;12(4):493–6.

    CAS  Article  Google Scholar 

  34. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep. 2005;13(4):589–95.

    CAS  PubMed  Google Scholar 

  35. Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1991;1062(1):77–82.

    CAS  PubMed  Article  Google Scholar 

  36. Lundbaek JA, Andersen OS. Lysophospholipids modulate channel function by altering the mechanical properties of lipid bilayers. J Gen Physiol. 1994;104(4):645–73.

    CAS  PubMed  Article  Google Scholar 

  37. Bancroft DP, Lepre CA, Lippard SJ. Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc. 1990;112(19):6860–71. doi:10.1021/ja00175a020.

    CAS  Article  Google Scholar 

  38. Nagai N, Okuda R, Kinoshita M, Ogata H. Decomposition kinetics of cisplatin in human biological fluids. J Pharm Pharmacol. 1996;48(9):918–24.

    CAS  PubMed  Article  Google Scholar 

  39. Miller SE, House DA. The hydrolysis products of cis-diamminedichloroplatinum(II). I. The kinetics of formation and anation of the cis-diammine(aqua)chloroplatinum(II) cation in acidic aqueous solution. Inorg Chim Acta. 1989;161(1):131–7.

    CAS  Article  Google Scholar 

  40. Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res. 2003;9(16 Pt 1):5807–9.

    CAS  PubMed  Google Scholar 

  41. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep. 2004;12(1):3–12.

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Centre for Post Graduate Studies and Research in Pharmaceutical Sciences, The Maharaja Sayajirao University of Baroda, Shri G.H. Patel Pharmacy Building, Donors’ Plaza, Fatehgunj, Vadodara, Gujarat, India, 390002

    Imran Vhora, Nirav Khatri, Jagruti Desai & Hetal Paresh Thakkar

Authors
  1. Imran Vhora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nirav Khatri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jagruti Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hetal Paresh Thakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hetal Paresh Thakkar.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vhora, I., Khatri, N., Desai, J. et al. Caprylate-Conjugated Cisplatin for the Development of Novel Liposomal Formulation. AAPS PharmSciTech 15, 845–857 (2014). https://doi.org/10.1208/s12249-014-0106-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-014-0106-y

Key Words

  • cisplatin
  • complexation
  • cytotoxicity
  • LD50
  • liposome